--- a
+++ b/clusters/9knumclustersv2/clust_1384.txt
@@ -0,0 +1,9 @@
+Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =<  effective half-lives prior to registration or who have not recovered from side effects of such therapy
+Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =<  effective half lives prior to starting study drug or who have not recovered from side effects of such therapy
+Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =<  effective half lives prior to starting study drug or who have not recovered from side effects of such therapy
+Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =<  effective half-lives prior to starting study drug or who have not recovered from side effects of such therapy
+Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =<  weeks (or =<  weeks for a monoclonal antibody) prior to starting study drug or who have not recovered from side effects of such therapy
+Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =<  effective half lives prior to starting study drug or who have not recovered from side effects of such therapy
+Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =<  effective half-lives prior to starting study drug or who have not recovered from side effects of such therapy
+Any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =<  effective half-lives prior to starting study drug or patients who have not recovered from side effects of such therapy
+Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =<  effective half lives prior to starting study drug or who have not recovered from side effects of such therapy (except alopecia)